



Clinical Benefits of Targeted Therapies in Patients with **Relapsed/Refractory DLBCL**

IN-PERSON + VIRTUAL SATELLITE SYMPOSIUM

FRIDAY, JUNE 3, 2022

7:00 PM - 9:00 PM CDT

PROGRAM CHAIR

Christopher R. Flowers, MD, MS, FASCO

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoPER.

WELCOME

Dear Colleague,

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **Hot Seat™: Expert Considerations to Maximize the Clinical Benefits of Targeted Therapies in Patients With Relapsed/Refractory DLBCL**.

This CME-certified satellite will provide you with expert perspectives on therapeutic strategies for the management of diffuse large B-cell lymphoma (DLBCL). The program includes a didactic lecture on risk assessment, the latest clinical trial data for new and emerging targeted agents, and approaches for the management of treatment-related adverse events. In the "Hot Seat" portion of the program, the moderator will ask a series of clinically important questions. For each question, you will have the ability to vote on which faculty member they would like to answer the question. This on-the-spot style of questioning is designed to replicate real-life decision-making scenarios when time is of the essence and decisions must be made quickly.

In working together with PER®, we strive to make this activity, along with all PER® accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients with DLBCL.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of cancer. Let's work together to make this an educational experience that will create a positive difference for our patients!

We hope you enjoy your experience at this first-class PER® satellites and that you can attend another PER® accredited CE activity soon.

Regards,

Christopher R. Flowers, MD, MS, FASCO

Division Head ad interim, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, TX

Phil Talamo, CHCP

President
Physicians' Education Resource®, LLC
Cranbury, NJ
ptalamo@gotoper.com

AGENDA

7:00 PM	Welcome and Faculty Introductions	
7:10 PM	The Latest Updates in R/R DLBCL and Rationale for Novel Emerging Approaches	
	Risk Assessment and Emerging First-line Treatment Landscape	Christopher R. Flowers, MD, MS, FASCO
	CAR T-cell Therapy in Second-line and Beyond	Frederick L. Locke, MD
	Relapsed DLBCL and Stem Cell Transplant	Laurie H. Sehn, MD, MPH
	Current and Emerging Novel Therapies for DLBCL	Kami J. Maddocks, MD
7:42 PM	Hot Seat: How Experts Sequence Therapies in Patients With R/R DLBCL	
8:32 PM	ASCO Annual Meeting Update	Christopher R. Flowers, MD, MS, FASCO
8:37 PM	Postassessment Questions	Christopher R. Flowers, MD, MS, FASCO
8:47 PM	Audience Q&A	All faculty
8:55 PM	Program Summary and Closing Remarks	Christopher R. Flowers, MD, MS, FASCO
9:00 PM	Adjourn	

Upcoming PER® Conferences			2022
●	6th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards		June 25
●	21st Annual International Congress on the Future of Breast Cancer® East	New York City, NY	July 15-16
●	6th Annual Live Medical Crossfire®: Hematologic Malignancies	New York City, NY	July 16
●	23rd Annual International Lung Cancer Congress®	Huntington Beach, CA	July 28-30
●	21st Annual International Congress on the Future of Breast Cancer® West	San Diego, CA	July 29-30
●	6th Annual School of Nursing Oncology	San Diego, CA	July 29-30
●	20th Annual School of Breast Oncology®	Atlanta, GA	November 3-5
●	40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®	New York City, NY	November 9-11
●	17th Annual New York Lung Cancers Symposium	New York City, NY	November 12
●	7th Annual International Congress on Immunotherapies in Cancer™	New York City, NY	December 10

● Virtual Conference ● In-Person + Virtual Conference

Target Audience

This educational activity is directed toward physicians involved in the treatment of DLBCL.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Determine DLBCL subtypes, biomarkers, and risk assessment methods, and how these factors inform treatment strategies for patients with relapsed/refractory (R/R) disease
- Evaluate the clinical profiles of current and emerging targeted therapies investigated for the treatment of R/R DLBCL
- Implement strategies to monitor and mitigate the impact of adverse events associated with targeted therapies among patients with R/R DLBCL
- Translate treatment guidelines and landmark trial data on targeted therapies to personalize sequencing strategies for patients with R/R DLBCL

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER[®] website by 12:00 PM EDT on Monday, June 6. To access these materials, please visit <https://www.gotoper.com/dlbcl0622iss-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit <https://www.gotoper.com/dlbcl0622iss-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain available until September 3, 2022.

Accreditation/Designation of Credit

Physicians' Education Resource[®], LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource[®], LLC designates this live activity for a maximum of 2.0 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from ADC Therapeutics America, Inc., Genmab US, Inc., Incyte Corporation, and Kite Pharma, Inc.

Thank you for attending **Hot Seat[™]: Expert Considerations to Maximize the Clinical Benefits of Targeted Therapies in Patients with Relapsed/Refractory DLBCL**

To register for upcoming accredited CE live activities or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER[®] accredited CE activities.

ACTIVITY OVERVIEW

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Other
Christopher R. Flowers, MD, MS, FASCO	AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research, Celgene, Collectis, Eastern Cooperative Oncology Group, EMD Serono, Gilead, Genentech/Roche, Guardant, Iovance, Janssen, Kite, MorphoSys, National Cancer Institute, Nektar Therapeutics, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, V Foundation, Xencor, Ziopharm	AstraZeneca, BeiGene, Bio Ascend, Bristol Myers Squibb, Celgene, Curio Science Denovo Biopharma, Epizyme/Incyte, Genentech/Roche, Genmab, MEI Pharma, MorphoSys, Pharmacyclics/ Janssen, Seagen	
Frederick L. Locke, MD	Allogene (Institutional), BlueBird Bio (Institutional), Bristol Myers Squibb (Institutional), Kite Pharma (Institutional), Leukemia and Lymphoma Society, National Cancer Institute, Novartis (Institutional)	Cowen, EcoR1 Capital LLC, Emerging Therapy Solutions, Gerson Lehrman Group (GLG)	Scientific Advisory Role: Allogene, Amgen, Bluebird Bio, Bristol Myers Squibb/Celgene, Calibr, Cellular Biomedicine Group, GammaDelta Therapeutics, Iovance, Kite Pharma, Janssen, Legend Biotech, Novartis, Sana Biotechnology, Takeda, Umoja BioPharma, Wugen Patents, Royalties, Other Intellectual Property: Several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy.
Kami J. Maddocks, MD		ADC Therapeutics, AstraZeneca, Beigene, Bristol Myers Squibb, Epizyme, Genentech, Incyte, Janssen, Kite Pharma, Lilly, MorphoSys, Seagen,	
Laurie H. Sehn, MD, MPH	Roche/Genentech, Teva	AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead/Kite Pharma, Incyte, Merck, Roche/Genentech, Sandoz, Seagen, TG Therapeutics	

**Information accurate at time of posting*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Program Chair

**Christopher R. Flowers, MD, MS, FASCO**

Division Head ad interim, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, TX

Christopher R. Flowers, MD, MS, FASCO, joined The University of Texas MD Anderson Cancer Center in Houston, Texas, in 2019 as chair of the department of lymphoma/myeloma and was appointed division head ad interim of cancer medicine in August 2020. Through the COVID-19 pandemic, Flowers's leadership contributed to the institution's recovery in patient volume while maintaining accelerated safety measures. Prior to joining MD Anderson, he was professor of hematology and oncology, with a joint appointment in biomedical informatics, at Emory University School of Medicine in Atlanta. During his tenure there, he served the Winship Cancer Institute as director of the lymphoma program for 13 years and as scientific director of research informatics for 4 years.

An internationally recognized expert in lymphoma clinical care, epidemiology, and outcomes research, Dr. Flowers is an innovator who has a passion for facilitating new drug development. He is an active clinician who conducts clinical research involving cancer outcomes, cancer informatics, and phase 1/2 trials focusing on the clinical development of novel therapeutics for B-cell lymphomas. His broader research interests include patient-oriented research in lymphoma and computer microsimulation models, and cost-effectiveness analyses aimed at developing strategies to individualize care for patients with cancer and improving systems of care. His work has resulted in more than 300 peer reviewed publications. He has received peer-reviewed funding from foundations and the National Institutes of Health, including leading multi-institutional team science grants such as the Lymphoma Epidemiology of Outcomes Cohort Study, the largest prospective study of lymphoma patients in the US.

Dr. Flowers earned his medical degree from Stanford University School of Medicine in California, where he also completed a master of science degree in medical informatics to gain expertise developing information systems to improve clinical research. He completed his internship and residency in internal medicine at the University of Washington in Seattle, where he continued his research training as a fellow in the Robert Wood Johnson Clinical Scholars Program and earned a second master's degree in pharmaceutical outcomes research and policy. During this time, he also completed his fellowship in medical oncology from the Fred Hutchinson Cancer Research Center, also in Seattle, Washington. Flowers has served in many capacities for national professional societies and has been elected to membership in the American Society for Clinical Investigation. In 2018, he was named a fellow of the American Society of Clinical Oncology (ASCO) and served as chair of both the ASCO guidelines on management of febrile neutropenia and ASCO health disparities committees. In the American Society of Hematology, Flowers has served as educational cochair for the annual meeting, a longstanding faculty member, and codirector of the Clinical Research Training Institute, and chair of the committee on promoting diversity. In each of these roles, he has committed to training and developing new leaders in hematology and oncology clinical research.

Faculty

**Frederick L. Locke, MD**

Vice Chair and Associate Member

Department of Blood and Marrow Transplant and Cellular Immunotherapy

Coleader, Immuno-Oncology Research Program

Research Director and Medical Director, Immune Cell Therapy Program

Moffitt Cancer Center

Tampa, FL

Frederick L. Locke, MD, is a medical oncologist and translational researcher in the department of blood and marrow transplant and cellular immunotherapy. He leads the immune cell therapy (ICE-T) initiative at Moffitt, which is an integrated cross-departmental translational team. Locke is a clinical research leader in the field of chimeric antigen receptor (CAR) T cell therapy, acting as a national principal investigator for several pivotal trials of anti-CD19 CARs for lymphoma. In addition, Dr. Locke is translating findings from his laboratory into new cellular immunotherapies such as the Moffitt-created whole protein surviving tumor vaccine for multiple myeloma. Dr. Locke earned his medical degree from Wayne State University in Detroit, Michigan. He stayed at Wayne State and the Detroit Medical Center for his residency in internal medicine and then served as chief medical resident at Detroit Receiving Hospital, which is a Level I trauma center. Locke received medical oncology, clinical research, and laboratory research training at the University of Chicago in Illinois. Dr. Locke provides care for multiple myeloma, lymphoma, and leukemia patients. He oversees both autologous and allogeneic hematopoietic stem cell transplants as well as cellular immunotherapy treatments such as CAR T cell Therapy.

**Kami J. Maddocks, MD**

Professor of Clinical Internal Medicine

Director, Lymphoma Research Program

Division of Hematology, Department of Internal Medicine

The James Cancer Hospital at The Ohio State University

Columbus, OH

Kami J. Maddocks, MD, is a professor of clinical internal medicine and director of the lymphoma program in the division of hematology at The James, The Ohio State University Comprehensive Cancer Center (OSUCCC). She specializes in treating patients with B-cell malignancies, including non Hodgkin lymphoma and Hodgkin disease. Maddocks conducts research evaluating new targeted therapies for these lymphomas, with a particular interest in aggressive lymphomas, including mantle cell and diffuse large B-cell.

Dr. Maddocks is an investigator for several clinical trials in lymphoma, most of which are evaluating nonchemotherapeutic approaches to the treatment of lymphoma and the role of minimal residual disease in predicting outcomes and making therapeutic decisions. She serves on the Alliance for Clinical Trials lymphoma committee, with a role as the chair for 2 mantle cell lymphoma trials through the Alliance Foundation Trials and the National Clinical Trials Network. Maddocks and colleagues at OSUCCC and Cornell University, Ithaca, New York, were awarded a Leukemia & Lymphoma Society and National Cancer Institute P01 to study functional genomics in mantle cell lymphoma therapy and mechanisms of resistance. She was senior author on the trial of tafasitamab and lenalidomide in relapsed diffuse large B-cell lymphoma that led to US Food and Drug Administration approval of the immune doublet in July 2020.

Faculty

**Laurie H. Sehn MD, MPH**


Chair, Lymphoma Tumour Group
 BC Cancer Centre for Lymphoid Cancer
 Clinical Professor of Medicine
 Division of Medical Oncology
 Associate Editor, Blood
 University of British Columbia
 Vancouver, British Columbia, CA

Laurie H. Sehn, MD, MPH, is currently clinical professor with the BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, in Vancouver, Canada. She has been a medical oncologist and clinical investigator at BC Cancer since 1998 and is currently the chair of the lymphoma tumour group.

Dr. Sehn graduated from McGill Medical School in Montreal, Quebec, Canada, and received her training in internal medicine at NewYork-Presbyterian/Columbia University Irving Medical Center in New York, New York. She was trained in hematology/oncology at Brigham and Women's Hospital and the Dana-Farber Cancer Institute, Harvard Medical School in Boston, Massachusetts, and received a master's of public health degree from the Harvard School of Public Health.

Prior to returning to Canada, she spent a year as faculty at the Dana-Farber Cancer Institute with its bone marrow transplantation service. Sehn's research interests include population-based outcomes analyses, identification of prognostic factors and predictive biomarkers, and development of novel therapies in lymphoma. She is chair of the medical advisory board for the international Lymphoma Coalition. She also has served as a member of the editorial board of the *Journal of Clinical Oncology* and *Leukemia & Lymphoma*. She currently is an associate editor for Blood. Sehn also serves as cochair of the lymphoma site of the Canadian Cancer Trials Group and cochair of the Lunenburg Lymphoma Biomarker Consortium.

Experience
 the new
 goto**per**.com



Streamlining
 education
 for the busy
 clinician



NOTES



NOTES

NOTES



ASCO Direct™

HIGHLIGHTS

2022 Official Annual Meeting Review

Learn from leading experts about important, potentially practice-changing data in oncology and hematology.

Dallas, TX
June 18

Charlotte, NC
July 9

Nashville, TN
July 9

New York, NY
July 23

VIRTUAL
OPTIONS
AVAILABLE

40% off registration! Use code **ADH22**



Scan with smartphone
to explore the series

PER®
Physicians'
Education
Resource, LLC
gotoper.com

**CELEBRATE THE 40TH ANNIVERSARY
OF CFS® LIVE IN NYC**

**40th Annual
CFS**®

Chemotherapy Foundation
SYMPOSIUM

Innovative Cancer Therapy for Tomorrow®

SAVE
THE
DATE!

NOVEMBER 9 – 11, 2022

New York Marriott Marquis • New York, NY

In-person + Virtual Conference

This activity
is approved
for AMA PRA
Category 1
Credit™.

 **100** EXPERT
FACULTY
MEMBERS

 **25** TUMOR
TYPES

 **3 DAYS**

 **1** MEETING

35% off registration! Use code **CFS22BF**



Scan with smartphone or visit the link below
gotoper.com/cfs22

PER®
Physicians'
Education
Resource, LLC
gotoper.com